INVESTOR NOTICE: Lundin Law PC Announces Securities Class Action Lawsuit Against PTC Therapeutics, Inc. and Reminds Investors with Losses to Contact the Firm

LOS ANGELES--()--Lundin Law PC announces a class action lawsuit has been filed against PTC Therapeutics, Inc. (“PTC Therapeutics” or the “Company”) (Nasdaq: PTC) concerning possible violations of federal securities laws between May 6, 2014 and February 23, 2016. Investors who purchased or otherwise acquired shares during the Class Period should contact the Firm in advance of the May 6, 2016, lead plaintiff motion deadline.

For more information or to participate, please contact Brian Lundin, Esquire, of Lundin Law PC, at 888-713-1033, or via e-mail at brian@lundinlawpc.com.

No class has been certified in the above action. Until a class is certified, you are not considered represented by an attorney. You may also choose to do nothing and be an absent class member.

According to the complaint, the Company failed to disclose that the NDA submitted to the FDA for Translarna was not complete enough to allow a substantive review of the application.

Lundin Law PC was created by Brian Lundin, a securities litigator based in Los Angeles.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.

Contacts

Lundin Law PC
Brian Lundin, Esq.
Telephone: 888-713-1033
Facsimile: 888-713-1125
brian@lundinlaw.com

Contacts

Lundin Law PC
Brian Lundin, Esq.
Telephone: 888-713-1033
Facsimile: 888-713-1125
brian@lundinlaw.com